This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, W. H. Search for Related Content PubMed PubMed Citation Articles by Miller, W. H., Jr.

Molecular Targets of Arsenic Trioxide in Malignant Cells

Lady Davis Institute for Medical Research, Sir Mortimer B. Davis Jewish General Hospital and McGill University Departments of Oncology and Medicine, Montréal, Québec, Canada

Correspondence: Wilson H. Miller, Jr., M.D., Ph.D., Professor of Oncology and Medicine, Sir Mortimer B. Davis Jewish General Hospital, 3755 Chemin De La Côte-Ste-Catherine, Montréal, Québec H3T 1E2, Canada. Telephone: 514-340-8222, ext. 3628; Fax: 514-340-7574; e-mail: Wmiller{at}ldi.jgh.mcgill.ca

Arsenic trioxide (As₂O₃; ATO) has considerable efficacy in the treatment of relapsed acute promyelocytic leukemia (APL), inducing partial differentiation and promoting apoptosis of malignant promyelocytes. Although initial studies focused on the role of the characteristic APL fusion protein, PML-RAR, in mediating response to ATO, subsequent investigations have revealed that ATO acts on numerous intracellular targets. ATO broadly affects signal transduction pathways and causes a wide range of alterations leading to apoptosis. Key mediators of sensitivity to ATO-induced apoptosis include intracellular glutathione and hydrogen peroxide (H₂O₂). The loss of inner mitochondrial membrane potential is also an important step in ATO-mediated cell killing. Cellular and physiologic pathways affected by ATO provide some clues as to the mechanisms for the biologic effects of ATO. Recent research has shown that hematologic cancers other than APL and solid tumors derived from several tissue types may be responsive to monotherapy or combination therapy with ATO. A better understanding of the mechanisms of action of ATO may help guide the use of ATO for the treatment of a wide variety of malignancies and allow its potential in cancer therapy to be fully realized.

Key Words. Arsenic trioxide • Apoptosis • Leukemia • Glutathione • Hydrogen peroxide • c-Jun-N-terminal kinase

This article has been cited by other articles:

				A. Yoda, K. Toyoshima, Y. Watanabe, N. Onishi, Y. Hazaka, Y. Tsukuda, J. Tsukada, T. Kondo, Y. Tanaka, and Y. Minami Arsenic Trioxide Augments Chk2/p53-mediated Apoptosis by Inhibiting Oncogenic Wip1 Phosphatase J. Biol. Chem., July 4, 2008; 283(27): 18969 - 18979. [Abstract] [Full Text] [PDF]

				E. H. Kim, M. J. Yoon, S. U. Kim, T. K. Kwon, S. Sohn, and K. S. Choi Arsenic Trioxide Sensitizes Human Glioma Cells, but not Normal Astrocytes, to TRAIL-Induced Apoptosis via CCAAT/Enhancer-Binding Protein Homologous Protein Dependent DR5 Up-regulation Cancer Res., January 1, 2008; 68(1): 266 - 275. [Abstract] [Full Text] [PDF]

				X. Zheng, A. Seshire, B. Ruster, G. Bug, T. Beissert, E. Puccetti, D. Hoelzer, R. Henschler, and M. Ruthardt Arsenic but not all-trans retinoic acid overcomes the aberrant stem cell capacity of PML/RAR{alpha}-positive leukemic stem cells Haematologica, March 1, 2007; 92(3): 323 - 331. [Abstract] [Full Text] [PDF]

				A. M. Ramos, C. Fernandez, D. Amran, P. Sancho, E. de Blas, and P. Aller Pharmacologic inhibitors of PI3K/Akt potentiate the apoptotic action of the antileukemic drug arsenic trioxide via glutathione depletion and increased peroxide accumulation in myeloid leukemia cells Blood, May 15, 2005; 105(10): 4013 - 4020. [Abstract] [Full Text] [PDF]

				D. Douer and M. S. Tallman Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies J. Clin. Oncol., April 1, 2005; 23(10): 2396 - 2410. [Abstract] [Full Text] [PDF]

				L. Zhou, Y. Jing, M. Styblo, Z. Chen, and S. Waxman Glutathione-S-transferase {pi} inhibits As2O3-induced apoptosis in lymphoma cells: involvement of hydrogen peroxide catabolism Blood, February 1, 2005; 105(3): 1198 - 1203. [Abstract] [Full Text] [PDF]

				Y. Moon, G. Park, Y. Kim, M. Kim, J. Lim, S. H. Pai, E. J. Lee, C. S. Kang, and K. Han Arsenic Trioxide (As2O3) Sensitivity of Carcinoma Cell Lines and Cancer Cells from Patients with Carcinomatosis Peritonei Ann. Clin. Lab. Sci., July 1, 2004; 34(3): 271 - 276. [Abstract] [Full Text] [PDF]

				A. Yacoub, C. Mitchell, J. Brannon, E. Rosenberg, L. Qiao, R. McKinstry, W. M. Linehan, Z.-s. Su, D. Sarkar, I. V. Lebedeva, et al. MDA-7 (Interleukin-24) Inhibits the Proliferation of Renal Carcinoma Cells and Interacts with Free Radicals to Promote Cell Death and Loss of Reproductive Capacity Mol. Cancer Ther., July 1, 2003; 2(7): 623 - 632. [Abstract] [Full Text] [PDF]

				Y. Zhou, E. O. Hileman, W. Plunkett, M. J. Keating, and P. Huang Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents Blood, May 15, 2003; 101(10): 4098 - 4104. [Abstract] [Full Text] [PDF]

				J. L. Slack, S. Waxman, G. Tricot, M. S. Tallman, and C. D. Bloomfield Advances in the Management of Acute Promyelocytic Leukemia and Other Hematologic Malignancies with Arsenic Trioxide Oncologist, April 1, 2002; 7(90001): 1 - 13. [Abstract] [Full Text] [PDF]